27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

NVCT Insider Trading (Nuvectis Pharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $565,748.85
Insider Selling (Last 12 Months): $0.00

Nuvectis Pharma Insider Trading History Chart

This chart shows the insider buying and selling history at Nuvectis Pharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Nuvectis Pharma Share Price & Price History

Current Price: $19.00
Price Change: Price Increase of +0.15 (0.80%)
As of 05/16/2022 05:00 PM ET

This chart shows the closing price history over time for NVCT up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

Nuvectis Pharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2022Kenneth HobermanDirectorBuy6,000$17.40$104,400.0055,140View SEC Filing Icon  
5/12/2022Kenneth HobermanDirectorBuy6,000$17.40$104,400.0055,140View SEC Filing Icon  
5/12/2022Ron BentsurCEOBuy12,245$16.99$208,042.552,957,704View SEC Filing Icon  
5/12/2022Shay ShemeshInsiderBuy1,278$15.85$20,256.301,240,893View SEC Filing Icon  
3/28/2022Ron BentsurCEOBuy4,000$7.05$28,200.00View SEC Filing Icon  
3/17/2022Ron BentsurCEOBuy7,000$7.63$53,410.00View SEC Filing Icon  
2/14/2022Ron BentsurCEOBuy8,000$5.88$47,040.00View SEC Filing Icon  
See Full Table
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades.

We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.

SEC Filings (Institutional Ownership Changes) for Nuvectis Pharma (NASDAQ:NVCT)

Nuvectis Pharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/12/2022BlackRock Inc.7,872$59K0.0%N/A0.062%Search for SEC Filing on Google Icon
5/11/2022Ronit Capital LLP550,000$4.08M5.1%N/A4.325%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Nuvectis Pharma logo
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Read More on Nuvectis Pharma

Today's Range

Now: $19.00
Low: $18.28
High: $19.96

50 Day Range

MA: $10.00
Low: $6.03
High: $19.00

52 Week Range

Now: $19.00
Low: $3.08
High: $19.97


34,758 shs

Average Volume

48,246 shs

Market Capitalization

$241.68 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Nuvectis Pharma?

Nuvectis Pharma's top insider investors include:
  1. Ron Bentsur (CEO)
  2. Shay Shemesh (Insider)
  3. Kenneth Hoberman (Director)
Learn More about top insider investors at Nuvectis Pharma.

Who are the major institutional investors of Nuvectis Pharma?

Nuvectis Pharma's top institutional shareholders include:
  1. Ronit Capital LLP — 4.32%
  2. BlackRock Inc. — 0.06%
Learn More about top institutional investors of Nuvectis Pharma stock.

Which major investors are buying Nuvectis Pharma stock?

In the previous quarter, NVCT stock was acquired by institutional investors including:
  1. Ronit Capital LLP
  2. BlackRock Inc.
In the previous year, these company insiders have bought Nuvectis Pharma stock:
  1. Ron Bentsur (CEO)
  2. Shay Shemesh (Insider)
  3. Kenneth Hoberman (Director)
Learn More investors buying Nuvectis Pharma stock.
"The Most Critical Metal for Global Economies"
The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year.
Find Out How This Is Good News